Secreted Phospholipase A2Inhibitors Are Also Potent Blockers of Binding to the M-Type Receptor
Authors:
- 14 October 2006
- journal article
- research article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 45 (44) , 13203-13218
Abstract
Mammalian secreted phospholipases A2 (sPLA2s) constitute a family of structurally related enzymes that are likely to play numerous biological roles because of their phospholipid hydrolyzing activity and binding to soluble and membrane-bound proteins, including the M-type receptor. Over the past decade, a number of competitive inhibitors have been developed against the inflammatory-type human group IIA (hGIIA) sPLA2 with the aim of specifically blocking its catalytic activity and pathophysiological functions. The fact that many of these inhibitors, including the indole analogue Me-Indoxam, inhibit several other sPLA2s that bind to the M-type receptor prompted us to investigate the impact of Me-Indoxam and other inhibitors on the sPLA2−receptor interaction. By using a Ca2+ loop mutant derived from a venom sPLA2 which is insensitive to hGIIA inhibitors but still binds to the M-type receptor, we demonstrate that Me-Indoxam dramatically decreases the affinity of various sPLA2s for the receptor, yet an sPLA2−Me-Indoxam−receptor complex can form at very high sPLA2 concentrations. Me-Indoxam inhibits the binding of iodinated mouse sPLA2s to the mouse M-type receptor expressed on live cells but also enhances binding of sPLA2 to phospholipids. Because Me-Indoxam and other competitive inhibitors protrude out of the sPLA2 catalytic groove, it is likely that the inhibitors interfere with the sPLA2−receptor interaction by steric hindrance and to different extents that depend on the type of sPLA2 and inhibitor. Our finding suggests that the various anti-inflammatory therapeutic effects of sPLA2 inhibitors may be due not only to inhibition of enzymatic activity but also to modulation of binding of sPLA2 to the M-type receptor or other as yet unknown protein targets.Keywords
This publication has 33 references indexed in Scilit:
- Oncogenic action of phospholipase A2 in prostate cancerCancer Letters, 2006
- The First Potent Inhibitor of Mammalian Group X Secreted Phospholipase A2: Elucidation of Sites for Enhanced BindingJournal of Medicinal Chemistry, 2006
- Group V and X secretory phospholipase A2 prevents adenoviral infection in mammalian cellsBiochemical Journal, 2005
- Arachidonic Acid Release from Mammalian Cells Transfected with Human Groups IIA and X Secreted Phospholipase A2 Occurs Predominantly during the Secretory Process and with the Involvement of Cytosolic Phospholipase A2-αJournal of Biological Chemistry, 2004
- In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2Science, 2004
- Role of Charge Properties of Bacterial Envelope in Bactericidal Action of Human Group IIA Phospholipase A2against Staphylococcus aureusJournal of Biological Chemistry, 2002
- Biological effects of group IIA secreted phosholipase A2FEBS Letters, 2002
- Pancreatic phospholipase A 2 via its receptor regulates the expression of key enzymes of phospholipid and sphingolipid metabolismThe FASEB Journal, 2001
- Generation of lyso-phospholipids from surfactant in acute lung injury is mediated by type-II phospholipase A2 and inhibited by a direct surfactant protein A-phospholipase A2 protein interaction.Journal of Clinical Investigation, 1998
- Insect paralysis by baculovirus-mediated expression of a mite neurotoxin geneNature, 1991